Ceftolozane/tazobactam

FDA

• Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
  • Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
• Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
• Complicated urinary tract infections (cUTI), including pyelonephritis
• Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)

Note: FDA indications for age ≥ 18 yrs

NON-FDA APPROVED USES

• Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])